WO2009019693A3 - Analgesic effect of jasmonate derivatives - Google Patents

Analgesic effect of jasmonate derivatives Download PDF

Info

Publication number
WO2009019693A3
WO2009019693A3 PCT/IL2008/001083 IL2008001083W WO2009019693A3 WO 2009019693 A3 WO2009019693 A3 WO 2009019693A3 IL 2008001083 W IL2008001083 W IL 2008001083W WO 2009019693 A3 WO2009019693 A3 WO 2009019693A3
Authority
WO
WIPO (PCT)
Prior art keywords
analgesic effect
jasmonate derivatives
jasmonate
derivatives
jasmonate derivative
Prior art date
Application number
PCT/IL2008/001083
Other languages
French (fr)
Other versions
WO2009019693A2 (en
Inventor
Max Herzberg
Rinat Borentshtain
Corrine Szilagyi
Original Assignee
Sepal Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepal Pharma Sa filed Critical Sepal Pharma Sa
Publication of WO2009019693A2 publication Critical patent/WO2009019693A2/en
Publication of WO2009019693A3 publication Critical patent/WO2009019693A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the treatment, alleviation or prevention of pain by administering a composition comprising a jasmonate derivative which binds to opioid receptors. The jasmonate derivative can be administered alone or in combination with one or more additional therapeutic agents.
PCT/IL2008/001083 2007-08-07 2008-08-07 Analgesic effect of jasmonate derivatives WO2009019693A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95432607P 2007-08-07 2007-08-07
US60/954,326 2007-08-07

Publications (2)

Publication Number Publication Date
WO2009019693A2 WO2009019693A2 (en) 2009-02-12
WO2009019693A3 true WO2009019693A3 (en) 2010-03-04

Family

ID=40341858

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2008/001083 WO2009019693A2 (en) 2007-08-07 2008-08-07 Analgesic effect of jasmonate derivatives

Country Status (1)

Country Link
WO (1) WO2009019693A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489981B (en) 2010-12-10 2015-07-01 柏萊迪健康科學有限責任公司 Use of jasmonate to treat bladder dysfunction
BR112013021670A2 (en) * 2011-02-25 2016-11-01 Nanocare Technologies Inc pharmaceutical formulation comprising compounds derived from metabolism, catabolism of jasmonate family members and their derivatives carried in micro and / or nanocarriers
EP2755643B1 (en) 2011-09-16 2019-05-08 Nanocare Technologies, Inc. Compositions of jasmonate compounds and methods of use
JP2018502855A (en) 2014-12-31 2018-02-01 ナノケア テクノロジーズ，インコーポレイティド Jasmonate derivatives and compositions thereof
KR102543754B1 (en) * 2021-09-15 2023-06-14 김민경 Injection composition for lipolysis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260758A1 (en) * 2004-02-27 2005-11-24 Lada Rasochova High efficiency peptide production in plant cells
US20060105915A1 (en) * 1999-06-30 2006-05-18 Marker Gene Technologies, Inc. Compositions and methods for targeted enzymatic release of cell regulatory compounds
US20060167102A1 (en) * 2002-02-04 2006-07-27 L'oreal S.A. Compositions comprising cyclopentane derivatives and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105915A1 (en) * 1999-06-30 2006-05-18 Marker Gene Technologies, Inc. Compositions and methods for targeted enzymatic release of cell regulatory compounds
US20060167102A1 (en) * 2002-02-04 2006-07-27 L'oreal S.A. Compositions comprising cyclopentane derivatives and their use
US20050260758A1 (en) * 2004-02-27 2005-11-24 Lada Rasochova High efficiency peptide production in plant cells

Also Published As

Publication number Publication date
WO2009019693A2 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX363178B (en) Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders.
MX366175B (en) Concentrated therapeutic phospholipid compositions.
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
WO2007149797A3 (en) Use of organic compounds
WO2007146712A3 (en) Therapy using cytokine inhibitors
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
MX350154B (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1 '-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain.
MX2014002171A (en) Combination treatments for hepatitis c.
MX2011008450A (en) Agonists and antagonists of the s1p5 receptor, and methods of uses thereof.
MX2012000488A (en) Combination therapy for the treatment of diabetes.
BRPI0713306A8 (en) PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE AND LOSARTAN
HK1176318A1 (en) Injection device
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
MX2009011900A (en) Diabetic wound healing.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2009019693A3 (en) Analgesic effect of jasmonate derivatives
WO2012012305A3 (en) Combination therapy using a ruthenium complex
TNSN08506A1 (en) Substituted carboxamides
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2011055383A3 (en) Intranasal delivery to improve the performance of children suffering from dyslexia
MX2010013484A (en) Pharmaceutical formulation of ketorolac for intranasal administration.
JO2820B1 (en) Combination of a Bisthiazolium Salt or a Precursor Thereof and Artemisinin or a Derivative Thereof for the Treatment of Severe Malaria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08789759

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08789759

Country of ref document: EP

Kind code of ref document: A2